Chemo plus anti–PD-1 before surgery for mouth cancer
Part of Cancer clinical trials.
This trial studies whether giving anti–PD-1 immunotherapy together with chemotherapy before surgery can improve outcomes for people with locally advanced, operable oral squamous cell carcinoma. It aims to shrink the cancer and make surgery more effective by treating both the tumor and the immune response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of oral squamous cell carcinoma from a biopsy (tissue sample).
- Your cancer is locally advanced but can be removed with surgery (no spread to distant organs).
- Tests like chest CT and PET/scan show no distant metastasis (no cancer spread).
- Your blood counts and organ tests are adequate (your doctor will check specific numbers for blood, liver, kidneys, and clotting).
- You are healthy enough to tolerate treatment (ECOG performance status 0–1).
- If you can become pregnant: a pregnancy test must be negative, and you and your partner must use birth control during the study and for up to 120 days after the last anti–PD-1 dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests medicines given before surgery for stage III/IV oral squamous cell carcinoma, choosing the treatment based on your tumor marker results. It aims to shrink the cancer and improve outcomes by using two targeted types of therapy.
This trial tests giving anti–PD-1 immunotherapy plus a drug called TP before surgery for oral squamous cell carcinoma (mouth/throat cancer). The goal is to see whether this pre-surgery treatment improves how much the tumor responds under the microscope.
This trial tests whether giving chemotherapy plus immunotherapy before surgery can help treat advanced mouth cancer. It aims to shrink tumors and improve outcomes.
This trial studies giving tislelizumab (an immune treatment) plus chemotherapy before surgery to shrink and treat locally advanced oral squamous cell cancer. It aims to improve tumor response and outcomes, while checking safety.
This trial tests a new immunotherapy drug (tirellizumab) combined with chemotherapy before surgery for early-stage oral cancer. It aims to see if this combination can help shrink the tumor and improve outcomes.
This trial tests whether adding targeted radiation (SBRT) to a combination of chemotherapy and immunotherapy before surgery can improve outcomes for people with advanced mouth or throat cancer. It aims to shrink the tumor more effectively before removal.
Hear when a new Oral Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.